Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.

Heredia A, Le N, Gartenhaus RB, Sausville E, Medina-Moreno S, Zapata JC, Davis C, Gallo RC, Redfield RR.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9412-7. doi: 10.1073/pnas.1511144112. Epub 2015 Jul 13.

PMID:
26170311
2.

Impact of HIV on lung tumorigenesis in an animal model.

Kawabata S, Heredia A, Gills J, Redfield RR, Dennis PA, Bryant J.

AIDS. 2015 Mar 13;29(5):633-5. doi: 10.1097/QAD.0000000000000588.

PMID:
25611150
3.

Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.

Latinovic O, Schneider K, Szmacinski H, Lakowicz JR, Heredia A, Redfield RR.

Antiviral Res. 2014 Dec;112:80-90. doi: 10.1016/j.antiviral.2014.10.006. Epub 2014 Oct 24.

PMID:
25453341
4.

Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV.

Heredia A, Natesan S, Le NM, Medina-Moreno S, Zapata JC, Reitz M, Bryant J, Redfield RR.

AIDS Res Hum Retroviruses. 2014 May;30(5):403-6. doi: 10.1089/AID.2013.0249. Epub 2014 Feb 7. No abstract available.

5.

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1.

Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR.

AIDS. 2014 Jan 28;28(3):317-23. doi: 10.1097/QAD.0000000000000168.

6.

Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1.

Heredia A, Davis CE, Reitz MS, Le NM, Wainberg MA, Foulke JS, Wang LX, Redfield RR.

J Infect Dis. 2013 Dec 15;208(12):2085-94. doi: 10.1093/infdis/jit395. Epub 2013 Aug 6.

7.

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke JS, Redfield RR, Heredia A.

AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb.

8.

CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Latinovic O, Reitz M, Le NM, Foulke JS, Fätkenheuer G, Lehmann C, Redfield RR, Heredia A.

Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12.

9.

Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.

Latinovic O, Kuruppu J, Davis C, Le N, Heredia A.

Clin Med Ther. 2009;1:1497-1510.

10.

Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.

Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.

Antiviral Res. 2009 Jul;83(1):86-9. doi: 10.1016/j.antiviral.2009.02.199. Epub 2009 Mar 9.

PMID:
19501260
11.

Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues.

Huang W, Groothuys S, Heredia A, Kuijpers BH, Rutjes FP, van Delft FL, Wang LX.

Chembiochem. 2009 May 4;10(7):1234-42. doi: 10.1002/cbic.200800741.

12.

Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20476-81. doi: 10.1073/pnas.0810843106. Epub 2008 Dec 15.

13.

An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, Reitz M.

J Virol. 2008 Jun;82(11):5460-71. doi: 10.1128/JVI.01049-07. Epub 2008 Mar 19.

14.

Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment.

Gilliam BL, Heredia A, Devico A, Le N, Bamba D, Bryant JL, Pauza CD, Redfield RR.

AIDS. 2007 Oct 1;21(15):2108-10.

PMID:
17885304
15.

CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.

Heredia A, Gilliam B, DeVico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, Redfield RR.

AIDS. 2007 Jun 19;21(10):1317-22.

PMID:
17545708
16.

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR.

Antimicrob Agents Chemother. 2007 Jul;51(7):2489-96. Epub 2007 May 7.

17.

HIV-1 natural viral suppressors: control of viral replication in the absence of therapy.

Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR.

AIDS. 2007 Feb 19;21(4):517-9.

PMID:
17301571
18.

Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.

Heredia A, Davis C, Bamba D, Le N, Gwarzo MY, Sadowska M, Gallo RC, Redfield RR.

AIDS. 2005 Dec 2;19(18):2087-95.

PMID:
16284457
19.

In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications.

Heredia A, Davis C, Amoroso A, Taylor G, Le N, Bamba D, Redfield RR.

AIDS. 2005 May 20;19(8):836-7.

PMID:
15867501
20.

Modification and structure-activity relationship of a small molecule HIV-1 inhibitor targeting the viral envelope glycoprotein gp120.

Wang J, Le N, Heredia A, Song H, Redfield R, Wang LX.

Org Biomol Chem. 2005 May 7;3(9):1781-6. Epub 2005 Apr 12.

PMID:
15858664
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk